Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia
| Autor: | Marko Lucijanic, Vlatko Pejša, Ozren Jakšić, Zeljko Prka, Marija Ivic, Zdravko Mitrović, Mario Piršić, Zeljko Jonjic, Anamarija Vrkljan Vuk, Tajana Štoos-Veić, Amina Fazlic Dzankic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Drug
obinutuzumab Cancer Research medicine.medical_specialty medicine.drug_class premedication media_common.quotation_subject Chronic lymphocytic leukemia Antibodies Monoclonal Humanized Gastroenterology corticosteroids 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Obinutuzumab Internal medicine Medicine Humans In patient Chronic lymphocytic leukemia obinutuzumab infusion related reactions premedication corticosteroids methylprednisolone media_common business.industry Hematology medicine.disease Leukemia Lymphocytic Chronic B-Cell methylprednisolone Oncology Methylprednisolone chemistry infusion related reactions 030220 oncology & carcinogenesis Corticosteroid chronic lymphocytic leukemia Premedication Autoimmune hemolytic anemia business 030215 immunology medicine.drug |
| Popis: | First obinutuzumab application is associated with infusion related reactions (IRRs) that may discourage further continuation of the drug. During our clinical practice we have observed that chronic lymphocytic leukemia (CLL) patients with autoimmune hemolytic anemia (AIHA) prolongedly receiving corticosteroids do not develop obinutuzumab IRRs. Therefore, we decided to apply prolonged corticosteroid premedication with methylprednisolone in dose 1–1.5 mg/kg for ≥7 days to all further obinutuzumab candidates. Here we present non-randomized comparison of 28 consecutive previously untreated CLL patients receiving prolonged corticosteroid premedication (15 patients) or standard premedication (13 patients) prior to the first obinutuzumab infusion. Prolonged corticosteroid premedication resulted in significant reduction of all-grade (20% vs 61.5% ; p = .025) and grade III (0% vs 23.1% ; p = .049) obinutuzumab IRRs. Prolonged corticosteroid premedication did not significantly affect occurrence of infective complications. Patients with CLL and AIHA receiving obinutuzumab showed continuous and stable increase in hemoglobin levels concomitantly with decrease in parameters of hemolysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|